Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vera Therapeutics Inc Cl A (VERA)

Vera Therapeutics Inc Cl A (VERA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Nov 11, 3:05PM CST

VERA : 49.00 (-0.87%)
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study GlobeNewswire - Mon Nov 11, 7:00AM CST

VERA : 49.00 (-0.87%)
Vera Therapeutics to Participate at Upcoming Investor Conferences GlobeNewswire - Fri Nov 8, 3:05PM CST

VERA : 49.00 (-0.87%)
Vera Therapeutics to Participate at Upcoming Investor Conferences GlobeNewswire - Fri Nov 8, 7:00AM CST

VERA : 49.00 (-0.87%)
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results GlobeNewswire - Thu Nov 7, 7:00AM CST

VERA : 49.00 (-0.87%)
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock GlobeNewswire - Tue Oct 29, 7:21PM CDT

VERA : 49.00 (-0.87%)
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock GlobeNewswire - Mon Oct 28, 4:37PM CDT

VERA : 49.00 (-0.87%)
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 GlobeNewswire - Sat Oct 26, 6:30PM CDT

VERA : 49.00 (-0.87%)
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Oct 4, 3:05PM CDT

VERA : 49.00 (-0.87%)
Could This Stock Be the Next Biotech Buyout? Motley Fool - Sat Apr 13, 4:29AM CDT

Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.

ALPN : 64.97 (+0.02%)
VRTX : 483.96 (-2.15%)
VERA : 49.00 (-0.87%)

Barchart Exclusives

Stock Index Futures Plunge as Fed Rate Cut Bets Wane, U.S. Retail Sales Data in Focus Barchart - 1 hour ago
December S&P 500 E-Mini futures (ESZ24) are down -0.58%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.90% this morning after Federal Reserve Chair Jerome Powell indicated the central bank was in no rush to lower interest rates, while investors geared up for a flurry of U.S. economic data, with a particular focus on the retail sales report. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot